Welcome to our dedicated page for Nls Pharmaceutics SEC filings (Ticker: NLSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NLSP SEC filings page provides access to the regulatory history of NLS Pharmaceutics Ltd. and its transition into NewcelX Ltd. through a merger with Kadimastem Ltd. As a foreign private issuer, the company reports primarily on Form 20-F and Form 6-K. Recent Form 6-K reports document key corporate events, including the completion of the merger on October 30, 2025, the 1-for-10 reverse share split, the name change to NewcelX Ltd., and the listing of the combined company on the Nasdaq Capital Market under the symbol NCEL.
Corporate and transactional filings include disclosures of the Agreement and Plan of Merger, shareholder approvals for capital structure changes, and details of the exchange ratio between NLS and Kadimastem shareholders. These filings explain how Kadimastem became a wholly owned subsidiary of the Swiss parent company, how the share capital was adjusted, and how contingent value rights were granted in connection with certain legacy NLS assets, such as Mazindol ER (excluding the DOXA platform).
Pipeline and collaboration updates are frequently furnished via Form 6-K as press releases. Examples include filings that attach announcements on the expansion of the DOXA CNS platform with the AEX-6xx series, continued BIRD Foundation support for the ITOL-102 diabetes program, strategic collaboration between Kadimastem and TargetGene on gene-edited cell therapies, and intellectual property milestones for IsletRx, such as the Hong Kong patent for cell-selection and enrichment technology.
Post-merger NewcelX disclosures appear under the NewcelX Ltd. name but remain linked to the same corporate issuer. These filings include press releases on the closing of the merger, business and strategic roadmap updates, shareholder letters, and leadership changes, such as the appointment of a new Chief Financial Officer. Together, they outline how the integrated biopharmaceutical company intends to advance its cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain the significance of each document, from transaction terms to pipeline developments. Users can quickly understand the main points of lengthy Form 6-K submissions, follow the evolution from NLSP to NCEL, and trace how regulatory disclosures reflect the company’s strategic direction and clinical priorities over time.
NewcelX Ltd., a Switzerland-based biotechnology company, reported that it issued a press release announcing the appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute, to its Scientific Advisory Board. The filing highlights that this appointment is intended to strengthen NewcelX’s scientific advisory capabilities by adding an experienced clinical leader to its advisory structure.
NewcelX Ltd. (NLSP) appointed Omri Hagai as Chief Financial Officer, effective December 10, 2025. He succeeds Interim CFO Uri Ben Or, who will step down the same day. The company stated Mr. Ben Or’s departure was not due to any disagreement with NewcelX regarding operations, policies, or practices.
The appointment follows the closing of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd. Mr. Hagai brings public‑company finance experience from Israel Chemicals, BrainsWay, and Saverone, and is a CPA in Israel.
NewcelX Ltd. filed Post‑Effective Amendment No. 2 to its Form F‑4, stating that it is being filed solely to (i) include Rule 473(b) language for automatic effectiveness 20 days following this filing, (ii) update the registrant’s name, and (iii) file updated Exhibits 23.2, 23.4 and 24.1; it does not modify the prospectus.
NLS Pharmaceutics previously registered 70,000,000 common shares and up to 70,000,000 pre‑funded warrants to purchase 70,000,000 NLS common shares in connection with the transaction. Shareholders approved the merger on September 29, 2025, setting the final ownership split at approximately 84.4% for Kadimastem holders and 15.6% for NLS holders. The merger closed on October 30, 2025, and NewcelX common shares began trading on Nasdaq as “NCEL” on October 31, 2025; the last reported sale price on November 4, 2025 was $5.65.
As of June 30, 2025, NLS reported cash and cash equivalents of $3.1 million and an accumulated deficit of $74.8 million, with a net loss of $2.22 million for the six months ended June 30, 2025. Kadimastem reported a net loss of $11.2 million for the same period, largely due to non‑cash revaluation of convertible loans, and cash of $298,932. Both parties highlight going‑concern risks and the need for additional financing.
NewCelX Ltd. filed a Form 6-K to furnish a press release and investor presentation issued on November 3, 2025. The materials provide a business and strategic roadmap update following the closing of NewCelX’s merger with NLS Pharmaceutics Ltd.
The filing itself mainly serves to formally provide these two documents to investors and regulators as Exhibits 99.1 and 99.2.
NLS Pharmaceutics (NLSP) completed its merger with Kadimastem on October 30, 2025, combining operations to form an integrated biopharmaceutical company focused on cell-based and small‑molecule therapies for neurodegenerative and metabolic diseases. In connection with closing, the company implemented a 1‑for‑10 reverse stock split and changed its name to NewcelX Ltd.
Shareholders approved the transactions on September 29, 2025. As part of closing, holders of NLS common shares, preferred shares, preferred participation certificates, and warrants received contingent value rights tied to potential future net proceeds from certain legacy asset dispositions, including Mazindol ER and excluding the DOXA platform.
NLS Pharmaceutics Ltd. filed a report noting that it issued a new press release about expanding its central nervous system (CNS) drug pipeline. The press release, titled “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs,” highlights a new series of CNS-focused compounds originating from Aexon Labs.
This step signals that NLS Pharmaceutics is adding additional product candidates to its research portfolio, potentially broadening its future development opportunities in neurological or psychiatric conditions, although no clinical, financial, or deal terms are described in this report.
NLS Pharmaceutics Ltd. furnished a 6-K reporting that, on October 29, 2025, it issued a press release titled “NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger.” The press release is included as Exhibit 99.1.
The filing indicates the company is highlighting ongoing support for the ITOL-102 diabetes program in the context of its merger with Kadimastem. The report is administrative in nature and provides the press release as an exhibit for investors’ reference.
FAQ
What is the current stock price of Nls Pharmaceutics (NLSP)?
What is the market cap of Nls Pharmaceutics (NLSP)?
